<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
Exhibit 27
Financial Data Schedule
Mylan Laboratories Inc. and Subsidiaries
Article 5 of Regulation S-X
The schedule contains summary financial information extracted from the
Consolidated Balance Sheets at March 31, 2000 and the Consolidated Statement of
Earnings for the twelve months ended March 31, 2000 and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<CIK> 0000069499
<NAME> Exhibit 27
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> MAR-31-2000
<PERIOD-END> MAR-31-2000
<CASH> 203,493
<SECURITIES> 99,557
<RECEIVABLES> 274,973
<ALLOWANCES> 77,212
<INVENTORY> 145,869
<CURRENT-ASSETS> 686,746
<PP&E> 273,581
<DEPRECIATION> 105,581
<TOTAL-ASSETS> 1,341,230
<CURRENT-LIABILITIES> 87,770
<BONDS> 25,104
0
0
<COMMON> 65,139
<OTHER-SE> 1,138,583
<TOTAL-LIABILITY-AND-EQUITY> 1,341,230
<SALES> 790,145
<TOTAL-REVENUES> 790,145
<CGS> 361,818
<TOTAL-COSTS> 361,818
<OTHER-EXPENSES> 205,368
<LOSS-PROVISION> 2,035
<INTEREST-EXPENSE> 390
<INCOME-PRETAX> 242,743
<INCOME-TAX> 88,497
<INCOME-CONTINUING> 154,246
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 154,246
<EPS-BASIC> 1.19
<EPS-DILUTED> 1.18
</TABLE>
